Combined chemotherapy plus radiotherapy for treatment of earlystage intermediate- and high-grade non-Hodgkin’s lymphoma

Current Oncology Reports

Volumn 2, Issue 2, 2000, Pages 176-181

  Briggs, Jonathan H ^a   Miller, Thomas P ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Clin Oncol; Combine Modality Therapy; Diffuse Large Cell Lymphoma; Lymphoma; Radiat Oncol Biol Phys

Indexed keywords

ANTINEOPLASTIC AGENT;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MALE; METHODOLOGY; MORTALITY; MULTIMODALITY CANCER THERAPY; NONHODGKIN LYMPHOMA; PATHOLOGY; PROGNOSIS; RADIATION DOSE; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, INTERMEDIATE-GRADE; LYMPHOMA, LOW-GRADE; LYMPHOMA, NON-HODGKIN; MALE; PROGNOSIS; RADIATION DOSAGE; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034156885     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-000-0091-z     Document Type: Article

References (45)

1. Shipp MA, Harrington DP: A predictive model for aggressive non-Hodgkin’s lymphoma: the International NHL Prognostic Factor Project. N Engl J Med 1993, 329:987–994. DOI: 10.1056/NEJM199309303291402
2. Romaguera JE, Velasquez WS, Silvermintz KB, et al.: Surgical debulking is associated with improved survival in Stage I-II diffuse large cell lymphoma. Cancer 1990, 66:267–272. DOI: 10.1002/1097-0142(19900715)66:2<267::AID-CNCR2820660213>3.0.CO;2-N
3. Aref A, Narayan S, Tekyi-Mensah S, et al.: Value of radiation therapy in the management of chemoresistant intermediate grade non-Hodgkin’s lymphoma. Radiat Oncol Investig 1999, 7:186–191. DOI: 10.1002/(SICI)1520-6823(1999)7:3<186::AID-ROI8>3.0.CO;2-2
4. Glick JH, Kim K, Earle J, O’Connell MJ: An ECOG randomized phase III trial of CHOP vs. CHOP plus radiotherapy for intermediate grade early stage non-Hodgkin’s lyphoma[abstract]. Proc ASCO 1995, 14:391a. This phase III ECOG trial demonstrates the benefit of the addition of involved-field radiotherapy in patients with bulky and extranodal stage I and stage II intermediate-grade lymphomas receiving CHOP chemotherapy. Patients receiving the combined modality approach had significantly improved disease-free survival and failure-free survival, whereas overall survival rates approached a significant improvement.
5. Fuller LM, Krasin MJ, Velasquez WS, et al.: Significance of tumor size and radiation dose to local control in stage I-III diffuse large cell lymphoma treated with CHOP-bleomycin and radiation. Int J Radiat Oncol Biol Phys 1995, 31:3–11. DOI: 10.1016/0360-3016(94)00343-J
6. Bagley CM, DeVita VT, Berard C, et al.: Advanced lymphosarcoma: intensive combination chemotherapy with cyclophosphamide, vincristine and prednisone. Ann Intern Med 1972, 76:227–234.
7. McKelvey EM, Gottlieb JA, Wilson HE, et al.: Hodroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976, 38:1484–1493. DOI: 10.1002/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I
8. Hoskins PJ, Ng V, Spinelli JJ, et al.: Prognostic variables in patients with diffuse large cell lymphoma treated with MACOP-B. J Clin Oncol 1991, 9:220–226.
9. Longo DL, DeVita VT, Duffey PL, et al.: Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol 1991, 9:25–38.
10. Coleman M, Armitage JO, Gaynor M, et al.: The COP-BLAM programs: evolving chemotherapy concepts in large cell lymphoma. Semin Hematol 1988,(suppl) 25:23–33.
11. Coiffier B, Gisselbrecht C, Herbrecht R, et al.: LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 1989, 7:1018–1026.
12. Fisher R, Gaynor E, Dohlberg S, et al.: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced NHL. NEJM 1993, 328:1002–1006. This SWOG trial convincingly demonstrates CHOP chemotherapy as the best available treatment for patients with advanced-stage intermediate-grade or high-grade non-Hodgkin’s lymphoma. Patients receiving the CHOP regimen had the same response rates and overall survival, but with a lower incidence of fatal toxicities, when compared with second- and third-generation regimens. DOI: 10.1056/NEJM199304083281404
13. Vokes EE, Ultmann JE, Golomb HM: Long-term survival of patients with localized diffuse histiocytic lymphoma. J Clin Oncol 1985, 3:1309–1317.
14. Bitran JD, Kinzie J, Sweet DL, et al.: Survival of patients with localized histiocytic lymphoma. Cancer 1977, 39:342–346. DOI: 10.1002/1097-0142(197701)39:1<342::AID-CNCR2820390151>3.0.CO;2-9
15. Kaminski MS, Coleman CN, Colby TV: Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiotherapy. Ann Intern Med 1986, 104:747–756.
16. Longo DL, Hathorn J: Current therapy for diffuse large-cell lymphoma. Prog Hematol 1987, 14:115–136.
17. Jones SE, Fuks Z, Kaplan HS, et al.: Non-Hodgkin’s lymphoma. V. Results of radiotherapy. Cancer 1973, 32:682–687. DOI: 10.1002/1097-0142(197309)32:3<682::AID-CNCR2820320322>3.0.CO;2-M
18. Sutcliffe SB, Gaspodarowicz MK, Bush RS, et al.: Role of radiation therapy in localized non-Hodgkin’s lymphoma. Radiother Oncol 1985, 4:211–223. DOI: 10.1016/S0167-8140(85)80086-4
19. Jones SE, Miller TP, Connors JM: Long term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy. J Clin Oncol 1989, 7:1186–1191.
20. Cabanillas F, Bodey GP, Freireich EJ: Management with chemotherapy only of stage I and II malignant lymphoma of aggressive histologic types. Cancer 1980, 46:2356–2359. DOI: 10.1002/1097-0142(19801201)46:11<2356::AID-CNCR2820461107>3.0.CO;2-X
21. Jeffrey GM, Mead GM, Whitehoue JMA, et al.: Involved field radiotherapy or chemotherapy in the management of Stage I nodal intermediate grade non-Hodgkin’s lymphoma. Br J Cancer 1991, 64:933–937.
22. Landberg TG, Hakansson LG, Moller TR, et al.: CVP-remissionmaintenance in stage I or II non-Hodgkin’s lymphoma. Cancer 1979, 44:831–838. DOI: 10.1002/1097-0142(197909)44:3<831::AID-CNCR2820440307>3.0.CO;2-S
23. Monfardini S, Banfi A, Bonadonna G, et al.: Improved five year survival after combined radiotherapy and chemotherapy for stage I-II non-Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 1980, 6:125–134.
24. Nissen NI, Ersboll J, Hansen HS, et al.: A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin’s lymphoma. Cancer 1983, 52:1–7. DOI: 10.1002/1097-0142(19830701)52:1<1::AID-CNCR2820520102>3.0.CO;2-M
25. Mauch P, Leonard R, Skarin A, et al.: Improved survival following combined radiation therapy and chemotherapy for unfavorable prognosis stage I-II non-Hodgkin’s lymphoma. J Clin Oncol 1985, 3:1301–1308.
26. Bajetta E, Valagussa P, Bonadonna G, et al.: Combined modality treatment for stage I-II non-Hodgkin’s lymphoma: CVP versus BACOP chemotherapy. Int J Radiat Oncol Biol Phys 1988, 15:3–12.
27. Ibrahim EM, Satti MB, Al-Idrissi HY, et al.: Combination chemotherapy only for stage II non-Hodgkin’s lymphoma. Eur J Cancer Clin Oncol 1986, 22:199–203. DOI: 10.1016/0277-5379(86)90031-3
28. O’Connel MJ, Harrington DP, et al.: Chemotherapy followed by consolidation radiation therapy for the treatment of clinical stage II aggressive histologic type non-Hodgkin’s lymphoma. Cancer 1988, 61:1754–1758. DOI: 10.1002/1097-0142(19880501)61:9<1754::AID-CNCR2820610906>3.0.CO;2-O
29. Connors JM, Klimo P, Fairey RN, et al.: Brief Chemotherapy and involved field radiation therapy for limited stage, histologically aggressive lymphoma. Ann Intern Med 1987, 107:25–30.
30. Longo DL, Glatstein E, Duffey P, et al.: Treatment of localized aggressive lymphomas: combination chemotherapy followed by involved field radiation therapy. J Clin Oncol 1989, 7:1295–1302.
31. Tondini C, Zanini M, Lombardi F, et al.: Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin’s Lymphomas. J Clin Oncol 1993, 11:720–725.
32. Villikka K, Muhonen T, Ristamaki R, et al.: Stage I non-Hodgkin’s lymphoma treated with doxorubicin-containing chemotherapy with or without radiotherapy. Acta Oncol 1997, 36:619–624.
33. Freilone BB, Vitolo U, Bertini M, et al.: Combined modality treatment with a weekly brief chemotherapy (ACOP-B) followed by locoregional radiotherapy in localized-stage intermediate to high-grade non-Hodgkin’s lymphoma. Ann Oncol 1996, 7:919–924.
34. Munck JN, Dhermain F, Koscielny S, et al.: Alternating chemotherapy and radiotherapy for limited-stage intermediate and high-grade non-Hodgkin’s lymphomas: long-term results for 96 patients with tumors >5 cm. Ann Oncol 1996, 7:925–931.
35. van der Maazen RW, Noordijk EM, Raemaekers JM, Meerwaldt JH. Combined modality treatment is the treatment of choice for stage I/IE intermediate and high-grade non-Hodgkin’s lymphomas. Radiother Oncol 1998, 49:1–7. This retrospective multi-institutional report comparing radiation therapy alone to CMT (chemotherapy followed by involved-field radiation therapy) in stage I/IE NHL demonstrates improved diseasefree and overall survival rates for patients receiving the combined approach. Recurrences were seen within 4 years of CMT, whereas recurrences were seen up to 10 years after radiation alone. DOI: 10.1016/S0167-8140(98)00066-8
36. Osterman B, Cavallin-Stahl E, Hagberg H, et al.: High Grade Non-Hodgkin’s Lymphoma Stage I. Acta Oncol 1996, 35:171–177.
37. Kamath SS, Marcus RB, Lynch JW, Mendenhall NP: The impact of radiotherapy dose and other treatment related and clinical factors on in-field control in stage I and II non-Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 1999, 44:563–568. This single-institution report examines the impact of radiation dose and failure patterns in patients receiving therapy for NHL. This study suggests that, in intermediate- and high-grade NHL, failure outside of the radiation field is common when RT alone is used. Radiation doses greater than 40 Gy may be necessary for better local control in this subset of patients. DOI: 10.1016/S0360-3016(99)00051-6
38. Ferreri AJ, Reni M, Ceresoli GL, et al.: Therapeutic management with adriamycin-containing chemotherapy and radiotherapy of monostotic and polyostotic primary non-Hodgkin’s lymphoma of bone in adults. Cancer Invest 1998, 16:554–561.
39. Pasini F, Cetto GL, Todeschini G, et al.: Combination of chemotherapy and radiotherapy improves the cure rate in primary extranodal lymphomas of the head and neck (PLHN). Anticancer Res 1997, 17:2837–2842.
40. Nathu RM, Mendenhall NP, et al.: Non-Hodgkin’s lymphoma of the head and neck: a 30-year experience at the University of Florida. Head Neck 1999, 21:247–254. This retrospective review of intermediate- and high-grade stage I and II NHL of the head and neck regions suggests that patients treated with combined modality therapy fare better than those receiving radiotherapy alone. Tumor size was an important factor for prognosis. DOI: 10.1002/(SICI)1097-0347(199905)21:3<247::AID-HED10>3.0.CO;2-6
41. Donato V, Iacari V, Aurlo A, et al.: Radiation therapy and chemotherapy in the treatment of head and neck extranodal non-Hodgkin’s lymphoma in early stage with a high grade of malignancy. Anticancer Res 1998, 18:547–554. This study retrospectively compares the therapy and outcome of patients with early-stage intermediate- and high-grade lymphoma. Although not statistically significant, patients receiving combined modality attained improved overall and disease-free survival rates, with less toxicity.
42. Miller TP, Dahlberg S, Cassady JR, et al.: Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate and high-grade non-Hodgkin’s lymphoma. N Engl J Med 1998, 339:21–26. This SWOG randomized trial comparing a standard course of chemotherapy alone with a combined modality regimen (chemotherapy followed by radiation therapy) demonstrates a significantly improved progression-free survival and overall survival for the CMT arm. There were fewer toxic events in the chemotherapy plus radiotherapy arm. DOI: 10.1056/NEJM199807023390104
43. Wylie JP, Cowan RA, Deakin DP: The role of radiotherapy in the treatment of the localized intermediate and high-grade non-Hodgkin’s lymphoma in elderly patients. Radiother Oncol 1998, 49:9–14. DOI: 10.1016/S0167-8140(98)00068-1
44. Oguchi M, Izuno I, Taki K, et al.: Treatment for Non-Hodgkin’s lymphoma (stage I, II) of the elderly: usefulness of local and regional irradiation and reduced dose chemotherapy. Int J Radiat Oncol Biol Phys 1997, 37:87–92. This prospective trial examines the use of local/regional radiation therapy with reduced-dose chemotherapy in elderly patients. Its results demonstrate the effectiveness of reduced-dose doxorubicinbased chemotherapy in the elderly with favorable control and survival rates, and a low rate of toxicity. DOI: 10.1016/S0360-3016(96)00470-1
45. Miller TP, Jones SE: Is there a role for radiotherapy in localized diffuse lymphomas. Cancer Chemother Pharmacol 1980, 4:67–70. DOI: 10.1007/BF00254024